Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Orchid Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
64/99

BSE: 524372 | NSE: ORCHPHARMA

NSE BSE
1143.55
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1144.00
  •  1146.00
  •  1125.00
  •  1134.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  16079
  •  183.48
  •  1459.70
  •  432.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,246.75
  • 78.63
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,114.66
  • N/A
  • 6.20

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.84%
  • 1.70%
  • 7.16%
  • FII
  • DII
  • Others
  • 1.42%
  • 17.78%
  • 2.10%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 2.11
  • 13.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 10.72

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -4.46
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.26
  • 2.76
  • 2.82

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.78
  • 56.84
  • 32.37

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
217.10
209.90
3.43%
220.59
159.76
38.08%
198.75
165.25
20.27%
182.92
130.99
39.64%
Expenses
188.18
170.21
10.56%
185.20
146.10
26.76%
175.44
147.43
19.00%
160.78
118.54
35.63%
EBITDA
28.92
39.69
-27.14%
35.39
13.66
159.08%
23.31
17.82
30.81%
22.14
12.45
77.83%
EBIDTM
13.32%
18.91%
16.04%
8.55%
11.73%
10.79%
12.11%
9.50%
Other Income
13.36
1.73
672.25%
7.62
8.93
-14.67%
8.36
5.84
43.15%
1.89
2.93
-35.49%
Interest
3.47
7.48
-53.61%
3.54
7.68
-53.91%
3.80
9.22
-58.79%
5.54
7.84
-29.34%
Depreciation
8.42
7.21
16.78%
9.27
8.18
13.33%
7.84
17.76
-55.86%
7.71
21.63
-64.36%
PBT
30.38
65.93
-53.92%
30.19
6.73
348.59%
20.02
-3.32
-
10.78
-14.09
-
Tax
-3.12
0.00
-
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
33.50
65.93
-49.19%
30.19
6.73
348.59%
20.02
-3.32
-
10.78
-14.09
-
PATM
15.43%
31.41%
13.69%
4.21%
10.07%
-2.01%
5.89%
-10.76%
EPS
6.50
14.49
-55.14%
5.80
1.86
211.83%
3.90
-1.32
-
1.85
-3.68
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 13
Net Sales
819.36
665.90
559.56
450.06
483.80
599.98
682.98
796.50
873.44
1,746.61
1,947.70
Net Sales Growth
23.05%
19.00%
24.33%
-6.97%
-19.36%
-12.15%
-14.25%
-8.81%
-49.99%
-10.32%
 
Cost Of Goods Sold
484.45
384.62
313.56
228.51
203.35
289.70
350.20
393.46
400.96
779.03
990.12
Gross Profit
334.91
281.28
246.00
221.56
280.45
310.28
332.79
403.05
472.47
967.58
957.58
GP Margin
40.87%
42.24%
43.96%
49.23%
57.97%
51.72%
48.73%
50.60%
54.09%
55.40%
49.16%
Total Expenditure
709.60
581.60
504.98
399.40
514.99
611.80
658.68
709.37
702.65
1,429.32
1,837.44
Power & Fuel Cost
-
61.26
52.74
39.31
47.44
48.76
50.69
54.33
55.28
102.19
121.72
% Of Sales
-
9.20%
9.43%
8.73%
9.81%
8.13%
7.42%
6.82%
6.33%
5.85%
6.25%
Employee Cost
-
65.35
63.28
67.11
74.86
82.28
86.22
80.25
86.81
193.82
252.70
% Of Sales
-
9.81%
11.31%
14.91%
15.47%
13.71%
12.62%
10.08%
9.94%
11.10%
12.97%
Manufacturing Exp.
-
35.55
32.88
29.10
53.25
55.98
65.65
87.40
94.33
182.40
226.41
% Of Sales
-
5.34%
5.88%
6.47%
11.01%
9.33%
9.61%
10.97%
10.80%
10.44%
11.62%
General & Admin Exp.
-
14.26
13.03
18.34
43.67
30.72
41.49
40.99
31.10
91.62
93.40
% Of Sales
-
2.14%
2.33%
4.08%
9.03%
5.12%
6.07%
5.15%
3.56%
5.25%
4.80%
Selling & Distn. Exp.
-
14.34
22.26
13.46
8.14
10.34
22.10
45.73
27.73
51.28
55.52
% Of Sales
-
2.15%
3.98%
2.99%
1.68%
1.72%
3.24%
5.74%
3.17%
2.94%
2.85%
Miscellaneous Exp.
-
6.22
7.22
3.59
84.27
94.02
42.34
7.21
6.44
28.97
55.52
% Of Sales
-
0.93%
1.29%
0.80%
17.42%
15.67%
6.20%
0.91%
0.74%
1.66%
5.01%
EBITDA
109.76
84.30
54.58
50.66
-31.19
-11.82
24.30
87.13
170.79
317.29
110.26
EBITDA Margin
13.40%
12.66%
9.75%
11.26%
-6.45%
-1.97%
3.56%
10.94%
19.55%
18.17%
5.66%
Other Income
31.23
19.43
9.00
15.21
24.28
16.93
20.30
19.17
24.91
42.47
40.72
Interest
16.35
32.90
33.46
52.21
6.23
6.69
310.26
331.11
294.24
537.12
522.69
Depreciation
33.24
54.79
87.02
108.92
117.93
129.94
133.31
141.02
145.27
324.58
251.92
PBT
91.37
16.04
-56.90
-95.25
-131.07
-131.52
-398.96
-365.82
-243.82
-501.95
-623.63
Tax
-3.12
0.00
0.00
0.00
0.00
0.00
-46.19
-48.04
-17.25
-191.46
-12.52
Tax Rate
-3.41%
0.00%
0.00%
0.00%
0.00%
0.00%
11.58%
8.92%
5.82%
49.27%
2.19%
PAT
94.49
55.25
-56.90
-95.25
-131.07
69.41
-352.77
-490.49
-279.11
-196.51
-558.02
PAT before Minority Interest
94.49
55.25
-56.90
-95.25
-131.07
69.41
-352.77
-490.49
-279.11
-197.13
-559.99
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.62
1.97
PAT Margin
11.53%
8.30%
-10.17%
-21.16%
-27.09%
11.57%
-51.65%
-61.58%
-31.96%
-11.25%
-28.65%
PAT Growth
71.02%
-
-
-
-
-
-
-
-
-
 
EPS
18.64
10.90
-11.22
-18.79
-25.85
13.69
-69.58
-96.74
-55.05
-38.76
-110.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 13
Shareholder's Funds
688.65
647.38
652.91
765.98
-704.04
-791.76
-387.67
49.04
329.39
379.99
Share Capital
40.82
40.82
40.82
40.82
88.96
88.96
88.96
88.96
85.26
70.45
Total Reserves
647.83
606.56
612.09
725.17
-793.00
-880.72
-476.63
-39.92
244.12
309.53
Non-Current Liabilities
164.67
222.40
442.26
518.98
1,435.53
1,904.62
2,204.95
2,475.41
2,609.35
1,064.40
Secured Loans
40.09
110.84
341.60
429.50
1,424.61
1,893.91
2,156.78
2,377.54
2,493.95
901.79
Unsecured Loans
108.75
97.32
85.90
74.47
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
12.60
11.01
11.54
11.79
7.70
7.48
2.07
3.73
4.18
5.24
Current Liabilities
371.89
240.78
142.08
174.94
2,345.54
2,012.51
1,540.72
1,337.62
1,122.66
3,206.03
Trade Payables
181.78
167.68
109.95
101.59
302.45
358.79
424.52
374.27
311.15
597.40
Other Current Liabilities
45.67
47.25
25.76
70.10
1,343.97
958.40
476.24
285.34
112.64
1,052.57
Short Term Borrowings
140.95
22.84
2.84
0.00
695.49
694.29
599.52
633.79
646.64
1,524.89
Short Term Provisions
3.49
3.01
3.52
3.25
3.63
1.03
40.44
44.22
52.23
31.17
Total Liabilities
1,225.21
1,110.56
1,237.25
1,459.90
3,077.03
3,125.37
3,358.00
3,862.07
4,061.40
4,651.04
Net Block
573.09
583.70
670.45
857.93
1,256.26
1,386.20
1,496.54
1,636.83
1,795.20
2,583.57
Gross Block
1,220.56
1,176.39
1,176.10
1,247.11
1,519.52
1,519.16
3,005.92
3,005.87
3,002.15
3,772.17
Accumulated Depreciation
647.47
592.68
505.66
389.18
263.26
132.96
1,509.38
1,369.04
1,206.95
1,188.60
Non Current Assets
724.20
712.91
687.39
890.58
2,309.57
2,446.42
2,478.86
2,610.87
2,783.27
3,549.62
Capital Work in Progress
46.46
9.78
7.43
25.61
278.16
271.53
288.31
280.40
281.51
360.42
Non Current Investment
44.44
45.49
0.40
0.34
0.47
1.07
0.96
0.81
0.81
0.95
Long Term Loans & Adv.
60.20
73.93
9.10
6.70
764.84
777.64
685.17
680.83
681.63
576.08
Other Non Current Assets
0.00
0.01
0.01
0.00
9.84
9.98
7.88
12.00
24.12
28.60
Current Assets
501.01
384.36
549.86
569.32
767.46
678.94
879.14
1,251.20
1,278.12
1,101.42
Current Investments
0.00
0.00
15.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
228.74
172.66
152.89
141.69
169.77
193.74
211.25
241.85
251.93
506.24
Sundry Debtors
215.19
170.57
135.70
67.97
119.89
119.51
203.00
310.07
256.57
179.06
Cash & Bank
30.63
8.06
19.91
174.04
325.52
305.55
257.06
314.94
390.56
23.42
Other Current Assets
26.45
13.01
130.47
21.57
152.28
60.14
207.82
384.34
379.06
392.69
Short Term Loans & Adv.
22.50
20.07
95.87
164.05
140.27
40.31
198.36
267.62
273.26
378.34
Net Current Assets
129.12
143.58
407.78
394.39
-1,578.08
-1,333.57
-661.58
-86.42
155.46
-2,104.61
Total Assets
1,225.21
1,097.27
1,237.25
1,459.90
3,077.03
3,125.36
3,358.00
3,862.07
4,061.39
4,651.04

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 13
Cash From Operating Activity
18.34
92.47
23.59
80.80
12.02
9.18
317.01
212.20
-369.07
168.17
PBT
46.32
-1.95
-116.53
-131.07
69.41
-398.96
-452.28
-296.18
-243.29
-572.51
Adjustment
51.38
36.77
172.15
139.57
57.34
453.49
582.11
490.19
1,006.39
661.19
Changes in Working Capital
-79.06
59.57
-36.96
61.89
-110.44
-38.31
187.17
18.19
-669.27
79.49
Cash after chg. in Working capital
18.64
94.38
18.66
70.38
16.30
16.22
317.01
212.20
93.84
168.17
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.30
-1.91
4.92
10.42
-4.28
-7.04
0.00
0.00
-47.03
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-415.87
0.00
Cash From Investing Activity
-31.21
112.94
67.21
167.11
45.47
-28.06
-8.59
-1.46
1,333.66
-986.04
Net Fixed Assets
-80.50
-2.64
89.19
430.14
-6.63
1,485.46
-7.97
-2.38
848.92
-751.02
Net Investments
-1.11
-33.59
-15.08
0.13
124.30
-0.11
-0.01
0.00
-0.47
24.72
Others
50.40
149.17
-6.90
-263.16
-72.20
-1,513.41
-0.61
0.92
485.21
-259.74
Cash from Financing Activity
31.17
-216.80
-164.99
-250.33
-0.30
33.39
-366.30
-286.36
-597.44
664.38
Net Cash Inflow / Outflow
18.29
-11.39
-74.20
-2.42
57.20
14.51
-57.88
-75.62
367.14
-153.49
Opening Cash & Equivalents
4.31
15.69
89.89
92.31
35.11
20.60
314.94
390.56
23.42
176.92
Closing Cash & Equivalent
22.60
4.31
15.69
89.89
92.31
35.11
257.06
314.94
390.56
23.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 13
Book Value (Rs.)
168.72
158.61
159.96
187.67
-79.14
-89.00
-43.58
5.51
38.63
53.94
ROA
4.73%
-4.85%
-7.06%
-5.78%
2.24%
-10.88%
-13.59%
-7.05%
-4.53%
-13.04%
ROE
8.27%
-8.75%
-13.43%
-423.17%
0.00%
0.00%
0.00%
-147.51%
-55.58%
-74.06%
ROCE
9.11%
-2.32%
-3.53%
-6.47%
3.08%
-3.46%
-6.93%
-0.06%
4.17%
-1.48%
Fixed Asset Turnover
0.56
0.48
0.37
0.35
0.39
0.30
0.27
0.29
0.52
0.57
Receivable days
105.72
99.89
82.59
70.86
72.82
85.57
115.97
116.98
45.27
27.22
Inventory Days
110.01
106.18
119.45
117.49
110.57
107.46
102.41
101.94
78.79
109.43
Payable days
165.82
161.59
168.95
136.49
197.80
198.57
186.30
148.72
86.46
100.90
Cash Conversion Cycle
49.91
44.47
33.09
51.86
-14.40
-5.54
32.07
70.20
37.60
35.76
Total Debt/Equity
0.48
0.41
0.69
0.74
-4.59
-4.04
-8.01
65.54
9.75
8.43
Interest Cover
2.68
-0.70
-0.82
-20.04
11.38
-0.29
-0.63
-0.01
0.28
-0.10

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India
    28th Jun 2024, 16:14 PM

    This collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research

    Read More
  • Orchid Pharma gets DCGI’s approval for Antibiotic Drug Combination of Cefepime and Enmetazobactam
    6th Jun 2024, 12:40 PM

    DCGI has also granted permission to manufacture and market Finished Dosage Form of Cefepime and Enmetazobactam as a dry powder injectable

    Read More
  • Orchid Pharma - Quarterly Results
    23rd May 2024, 20:17 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.